Cormorant Pharmaceuticals

Cormorant Pharmaceuticals is a recently founded biopharmaceutical company focusing on the development of therapeutics for the treatment of cancer and rare diseases. Cormorant Pharmaceuticals’ business model is based on the principle of combining new research findings with existing drug substances in order to bring innovation faster to the patient. The company is privately held and based in Stockholm, Sweden Currently, we our IL-8 antibody HuMax-IL8 is being tested in a phase I trial in patients with solid tumors. Our vision for this project is that the inhibition of IL-8 will target the aggressive behaviour of cancer cells and cancer stem cells in several cancer forms. IL-8 inhibition also has the potential to reduce tumor immunosuppression through MDSCs (myeloid derived suppressor cells). HuMax-IL8 will be a first in class agent with possibility to target many different tumor types and to be combined with other treatments, due to a good safety profile.